Fruquintinib Combo Shows Activity in Pretreated Metastatic CRC
Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.
Related Articles
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer
Guo et al. trace immune cell dynamics in patients with hepatocellular carcinoma (HCC) receiving neoadjuvant anti-PD-1 plus lenvatinib by single-cell multi-omics technologies. Compared with anti-PD-1 monotherapy,…
Episode 180: Reducing the Pain of Cancer Patients, with Dr. Whitney Luke
The James Cancer Hospital is a leader is helping cancer patients deal with the pain that can be associated with treatment. “Our inpatient oncology rehabilitation…
4 questions for mathematical oncologist Heiko Enderling, Ph.D.
Get to know mathematic oncologist Heiko Enderling, Ph.D., including how he got his start in research, what excites him the most about working at MD…
Therapy-Related Myeloid Tumors in Neuroendocrine Neoplasms After Peptide Receptor Radionuclide Therapy
This systematic review evaluates the literature and reports the incidence, time of diagnosis, and nature of therapy-related myeloid neoplasms after peptide receptor radionuclide therapy.
Melissa Loh: Protocol paper on our multicenter UR-GOAL study – OncoDaily
Melissa Loh: Protocol paper on our multicenter UR-GOAL study / cancer, Craig Maguire, Daniel Richardson, Eric J. Huselton, Heidi D. Klepin, Jane Liesveld,
Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
Dr. Brian Wolpin discusses updated safety and efficacy results from the Phase 1 study of RMC-6236, a RAS(ON) multi-selective inhibitor, highlighting its promising activity, manageable…
Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer
The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.
The Grotzinger Lecture: A Revered Tradition at Fox Chase Cancer Center
Members of the Fox Chase Cancer Center community gathered on January 21, 2025 for the Paul J. Grotzinger, MD, Memorial Lecture.
Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer
An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.